Summary: Precision medicine, employing genome-guided biomarkers and therapeutic strategies, has changed clinical trial recruitment and reporting. An increasing number of clinical trials have an eligibility component requiring the absence or presence of a specific molecular variant to validate predictive biomarkers that inform or recommend therapeutic action.
